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Gastric cancer is one of the most commonly diagnosed cancers found in the world (980,000 new cases in 2008), but 
its treatment outcomes are poor, particularly in the European Union (EU); only a 25% survival after 5 years. Despite 
advances made in combination therapy, the only effective treatment that remains is surgery. The extent of gastric 
resection and lymphadenectomy, along with reconstruction methods, have systematically evolved over the last 100 
years. This paper discusses both present day recommendations and the pathways that were taken enabling modern 
gastric surgery to develop.
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Introduction
Although gastric cancer (GC) morbidity has been stead-
ily falling over the last 100 years or so, it still remains the 
fourth most common cancer in the world; in 2008 there were 
980,000 new cases globally, of which 83,000 occurred in the 
EU and over 5,000 in Poland [1, 2]. Enduring dietary changes 
and decreases in chronic Helicobacter Pylori infections have 
led to decreased morbidity in all developed countries of 
the world within the last 50 years [1]. This however does 
not translate into a satisfactory rates of those surviving; the 
5 year survival for GC in Europe is around 25%, whereas in 
Japan it is 70% [3, 4]. A significant cause for this large differ-
ence is that Japan undertakes a screening programme that 
enables 70% of diagnoses to be made of early GC, whilst in 
Poland the rates are never higher than 6.7%. The promising 
advances made in chemo-/radio-therapies have not altered 
the fact that still the only method remaining for successfully 
treating GC is surgery. 
Historical outline
In spite of the centuries old tradition of performing 
stomach operations, a breakthrough occurred with the 
advent of when antiseptics and anaesthesia were discov-
ered. Before the introduction of anaesthesia, attention was 
however only focused on making a gastric fistula which 
could extend patient life/survival and halt the spectre of the 
patient starving to death. The first such fistula was made by 
an American army doctor, William Beamont in 1822, who 
was treating a trapper with a bullet wound. A partial gas-
trectomy, because of cancer, was first performed in Paris on 
April 1879 by Jules Pean, however the patient died shortly 
afterwards. Another attempt at removing a gastric tumour 
was made in Celm on November 1880 by Ludwig Rydygier 
[5, 6]; also with no success. It was only Theodor Billroth 
on January 1881, who managed to successfully undertake 
a pylorus resection, including the tumour, followed by anas-
tomy of the proximal stomach to the duodenum; this type of 
reconstruction is to this day termed a ‘Billroth I’. Even though 
the operation was successful, the patient later died because 
of recurrence. Billroth then encouraged by the experimental 
work by his pupil Wolffler, subsequently performed an anas-
tomy of the stomach to the jejunum after shutting off and 
resecting a cancer of the duodenum, thus duodenal passage 
is bypassed; this procedure being termed the ‘Billroth II’. 
The first successful total gastrectomy (TG) was undertaken 
in 1897 by Schlatter on a 56 year-old patient who survived 
for 14 months but then died of metastases. Subsequent 
attempts however did not proceed so smoothly, where 
the mortality after such operations was high. It should be 
remembered that the extent of such interventions relies on 
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just removing parts of the pyloric antrum, and it should also 
be noted that a lymphadenectomy was not even considered. 
A therapeutic success was then considered as one reducing 
symptoms and prolonging life by 2–3 years [5, 6]. Attempts 
to improve outcomes were based on changing surgical 
techniques and methods of reconstruction; but to no avail. 
For many years the Hoffmeister method remained one of the 
most popular ways of reconstruction, involving the closing 
of the stomach at its lesser curvature and anastomy to the 
greater curvature of the intestinal loop. 
High mortality rates, preoperatively, meant that until the 
1940s of the last century gastrectomies were performed ex-
tremely rarely. Until 1929, only 62 cases of TG were published 
throughout the world and the mortality rate exceeded 50% [7]. 
The decrease in perioperative mortality occurred due to 
the introduction of antibiotics, blood transfusion and ad-
vances made in analgesia and anaesthesia. Nonetheless, up 
to the 1970s, the post-TG mortality risk reached 20%. It was 
not until advances had been made in enteral and parenteral 
nutrition, as well as in intensive care, at the end of the 1980s 
that the mortality rate fell below 5% [8, 9].
The extent of resection
The beginnings of gastric surgery were mainly devoted to 
dealing with disease symptoms. Developments in pathological 
anatomy, physiology and oncology led an evolutionary change 
in the approach and scope of surgical operations, eventually 
leading to the concept of regional operating theatres. The aim 
of surgery is to remove both the tumour and lymph nodes, 
thereby minimising the risk of relapse. Nevertheless, the grow-
ing importance of chemo- and radio-therapy used in combina-
tion therapy does not relieve the surgeon of responsibility for 
curing GC. Following the time when the extent of resection 
was being maximised, (arising from pinning excessive hopes 
for curing cancer by these means), compromise solutions are 
now sought for in trade-offs between the risk of relapse and 
quality of the patient’s life (QoL) after treatment. What then 
should be the extent of gastric resection/gastrectomy? This 
should depend on the size, type and location of the tumour. The 
QoL in TG patients is worse than those when SG is used [10, 11]. 
If an appropriate macroscopic margin is preserved, then 
any partial surgical resection does not lower the chances 
for effecting a cure and it improves the QoL. Evidence for 
this was provided by prospective studies of Gouzi, Bozzetti 
and Davies [11–14]. Most researchers consider that 4–5 cm 
is a safe enough margin for intestinal tumours, but 6–8 cm 
for diffuse tumours; according to Lauren [11, 14–16]. A ret-
rospective study by Harrison et al. evaluated 98 patients 
with cancer in the proximal part of the stomach, (65 after 
SG and 33 after TG), and found no differences in survival or 
recurrence rates, however the QoL had not been measured. 
Indeed, there is no prospective study data in the literature 
that takes into account QoL in both such groups.
Hundhal et al. summarised treatment outcomes for pa-
tients operated on in the USA, during 1985–1996. Only 18% 
patients underwent D2 lymphadenectomy; in line with UICC 
classification of > 15 lymph nodes/sample. More than half 
the patients were at clinical stages III and IV of advancement 
and less than 1/3 had a tumour located in the distal part of 
the stomach. In spite of the limited indications for partial 
gastrectomy, a complete excision was undertaken in only 
40% cases [17]. Siewert reported on treatment outcomes in 
1654 patients from German and Austrian centres: 30% tu-
mours were located in the distal part of the stomach, 39.9% 
in the middle and 26% in the proximal [18]. A subtotal distal 
gastrectomy was performed only in 23.1% of patients, whilst 
the others underwent total or total extended gastrectomies 
for tumours of the gastroesophageal junction. Extending the 
extent of resection to those neighbouring organs that are 
infiltrated, increases the risk of complications and mortality 
during the perioperative period [19, 20]. However in certain 
cases of infiltration/invasion, particularly for node-negative 
stage patients, the chances of recovery are significantly af-
fected [21–24]. Splenectomy and splenopancreatectomy 
had no effect on survival compared to resection limited 
by an analogous lesion progression according to the UICC 
classification [21]. Prospective studies have not yielded any 
data on the effects of splenectomy on treatment outcomes. 
Nonetheless, removing lymph nodes from the splenic cav-
ity whilst preserving the organ can prove difficult. A vitally 
important and still much debated issue is the extent of the 
lymphadenectomy. The success of Japanese surgeons in 
treating GC was initially confirmed by retrospective studies 
and led to defining the range of the so-called standard (D1) 
and the extended (D2) lymphadenectomies. Furthermore, 
it is accepted that for correctly assessing the tumour stage, 
at least 15 lymph nodes are required present for a D1 and 
at least 25 for a D2. The classification of lymphadenectomy 
ranges made by the Japanese Research Society for Gastric 
Cancer is shown in Figure 1. Studies by Maruyama et al. 
have proved the advantage of performing a D2 lympha-
denectomy over D1. The difference in 5-year survival rates 
was significant; 61.6% vs 44.3% [25, 26].
The difficult-to-replicate Japanese studies in Western 
countries have prompted prospective European studies to 
be undertaken. The largest of these was a study by Bonen-
kamp et al. (Dutch Gastric Cancer Group), in which 632 
patients were randomised into two lymphadenectomy 
groups: D1 or D2. The differences in 5-year survival proved 
to be insignificant, nevertheless significant differences were 
respectively observed for the following: complications (25% 
vs 43%) and perioperative mortality (4% vs 10%) [19]. One 
drawback pointed out for the Dutch study is the limited 
experience of surgeons performing the extended lymphad-
enectomies, which may also increase the risk of complica-
tions, including deaths; most of the centres performing less 
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than 10 gastric operations annually. The D2 operation was 
similarly found to be inferior in a study by Cushieri et al. on 
400 patients [20]. Upon investigating the sub-groups from 
these two studies, then the increasing complications and 
perioperative mortality rates were found to apply to those 
patients that underwent extended resection for splenecto-
my and/or distal pancreatectomy. If such cases are excluded 
from the assessment, then mortality and complications 
become similar for both groups. Moreover, at clinical stage II 
and III A, the survival is significantly longer in the D2 group. 
This is confirmed by an extended lymph node dissection 
study from Holland [27], a study by Edwards et al. (5-year 
survival 32% vs 59% in favour of D2), Siewert and a German 
group, where patients at clinical stage II showed 49.2% vs 
19.9% rates (i.e. a 30% difference favouring D2) as well as 
by other Japanese researchers [18, 26–28]. A study by Sano 
[29] surveyed selected centres specialising in gastric surgery 
(i.e. above 80 gastrectomies annually) and showed that both 
D2 and D2+ lymphadenectomies (extended by the para-
aortic nodes) can be safely performed by experienced sur-
geons (mortality 0.8%). Evidence is lacking that any further 
extension of lymphadenectomy improves patient survival, 
which was confirmed by studies from the Cracow-based 
centre; Kulig et al. [30, 31].
The standard treatment of gastric adenocarcinoma is 
currently the complete/almost complete excision of the 
stomach (a margin/boundary of at least 5 cm) together with 
regional D2 lymphadenectomy. The area of lymphadenecto-
my can be limited to D1 (lymph nodes around the stomach) 
for T1N0 advancement. The area of D2 lymphadenectomy 
includes the lymph nodes of the celiac artery, the left gastric 
artery, common hepatic artery and the surroundings of the 
splenic artery along with the hilus lienis (splenic cacity) 
which in isolated cases may require selective removal of 
Figure 1. Extent of resected gastric lymph nodes (according to the Japanese Research Society for Gastric Cancer)
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the spleen, whilst sparing the pancreas. Obligatory stand-
ards of conduct for treating gastric cancer are summed 
up by the American College of Surgeons (Tab. I) [16]. 
Despite attempts for globally harmonising standards, there 
are important differences in how the extents of radical resec-
tion are approached between Asia with the US and Europe. 
In Western countries, the recommended margins for achiev-
ing a curative resection (RO) through TG or SG is a 4 cm 
minimum according to the NCCN or 5–8 cm by ESMO or a D1 
or D2 lymphadenectomy (without elective pancreatic resec-
tion/splenectomy) at a minimum of 15 lymph nodes being 
present [32–33]. Japanese recommendations give a margin 
of 2–5 cm depending on the T and G tumour characteris- 
tics [34]. Other differences are in the extent of lymphadenec-
tomy. In contrast to the Japanese, recommendations for D1 
according to Western countries does not include the lymph 
nodes of left gastric artery. Such differences make it indeed 
difficult to compare treatment outcomes (Fig. 1).
Reconstruction methods following  
total gastrectomy 
The aim of reconstruction in the GI tract is to restore the 
function of a given resected organ by as far as is possible, so 
enabling a reversion back to an independent status. Up till 
now there are 50 ways proposed for reconstruction, post-
-gastrectomy, but all can be divided into two basic groups 
according to whether duodenal passage has been preserved 
or not. Both these approaches can be performed in straight-
forward fashion and are complemented by constructing an 
intestinal reservoir pouch. A third group uses double-tract 
methods which reduces the risk of ischemia as well as linking 
the benefits arising both from retaining duodenal passage 
and in constructing an intestinal reservoir pouch.
The method of reconstruction after TG as proposed by 
Schlatter, [7] consisted of oesophageal anastomosis with 
the intestinal loop pulled up and when completed by intra-
intestinal anti-reflux anastomosis, this procedure dominated 
the 1940s. Unfortunately, most patients reported symptoms 
of reflux oesophagitis [35, 36]. Likewise, for these same 
reasons duodenoesophagostomies, as proposed in 1898 
by Brigham and then propagated by Nakayama and Hinze, 
have now been abandoned. It was only in 1909 that a recon-
struction of the Y-loop improved the QoL as proposed by 
Cesar Roux in Lausanne (originally for SG and later adapted 
for TG) (Fig. 2). The favourable outcomes achieved by this 
method had been confirmed by numerous studies in the 
1940s. A modification proposed by Orr in 1947 involving 
anastomosis of the end of the oesophagus to the side of the 
intestinal loop (intended to reduce tension and improve the 
blood supply to the anastomosis), ultimately determined 
today’s most popular method for reconstruction of the di-
gestive tract after total gastrectomy [9]. Its main advantage 
is that it is simple to perform and it effectively prevents 
reflux of bile into the oesophagus, whereas its disadvan-
tage is the absence of duodenal passage. A reconstruction 
procedure that preserved duodenal passage was (jejunal 
segment interposition first undertaken in 1941 by Seo and 
subsequently modified and propagated by Longmire and 
Henley (Fig. 3). Maintaining the passage of food through the 
duodenum allows at least to partially preserve the hormonal 
regulation of the gastrointestinal tract function as well as 
providing endoscopic access to the duodenum and bile 
ducts (Figs. 2, 3) [37–40].
From the time when the Roux-en-Y syndrome was first 
described by Mathias, greater weight is given to retaining 
the continuity used to reconstruct the intestinal loop, which 
is designed to protect against peristaltic wave disorders 
in the intestine and symptoms of pronounced pseudo- 
intestinal obstruction. In the opinion of this study group, 
such measures when taken improves the patient’s QoL, 
especially in the first year after TG [41]. Apart from restor-
ing gastrointestinal passage another important issue after 
TG it is to prevent reflex disease arising from the lack of the 
pylorus and lower oesophageal sphincter. The most effective 
safeguard appears to be in keeping sufficient distance be-
tween the oesophageal-intestinal and biliary anastomosis. 
A distance of around 7 cm was originally proposed by Roux 
for the reconstruction; in the 1950s Wells and Johnston 
lengthened this to 20–25 cm, whilst nowadays the majority 
of workers suggest 40–60 cm. In reconstructing intestinal 
interpositions, whilst maintaining duodenal passage, it was 
initially postulated that the loop length be is less than 20 cm.
Table I. Surgical treatment of gastric cancer NCCN vs ESMO Consensus 
Am Coll Surg 2013 [16]
Resection extent Proximal tumour — TG
 Distal tumour — SG/TG
Lymphadenectomy T1N0 — D1
T > 1N > 0 — D2
Minimum 15 lymph nodes in surgical 
sample after radical surgery 25 lymph 
nodes
Organ resection Splenectomy — electively NO
Bursectomy — electively NO
Cholecystectomy — electively NO,  
only for cholelithiasis
Margins < 5 cm ad-hoc studies, cutting into 
positive margins (R1) 
Reconstruction After SG — Roux-en-Y 
 After TG — Roux-en-Y
                 — Roux-en-Y + reservoir 
Post-surgery nutrition Jejunostomy — after TG
TPN — Lack of consesus
Others Poll — lack of consensus
Routine sealing — lack of consensus
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In 1952, Longmire proposed a longer length, whilst 
Gutgenam in 1966 confirmed that a loop of 30–35 cm sig-
nificantly reduced the risk of reflux disease [38, 39, 42, 43]. 
An anti-reflux role for jejunoplication was proposed by 
Schreiber and performed by an end-to-side esophagoje-
junostomy and using the ‘blind’ intestinal loop [44, 45]. 
Gorka however proposed an invagination technique when 
performing end-to-end esophagojejunostomy through 
extending the anastomosis to the first line of the intestine 
at a depth of 4–5 cm, which both protects against leakage 
during the perioperative period and creates/affords an anti-
reflux mechanism [46]. A favourable anti-reflex outcome can 
also be obtained by a reconstruction using the ileo-caecal 
segment and Bauhin’s valve. This method was propounded 
by Lee and Hunnicutt in the early 1950s which at the same 
time allowed restoration of the stomach’s function as a gas-
tric food reservoir [47, 48]. Prospective studies have indeed 
confirmed the efficacy of this anti-reflux procedure, however 
other adverse consequences are diarrhoea or halitosis and 
no gains in QoL nor in other nutritional parameters over 
other technically much simpler ways of reconstructing; this 
now leading a decreased popularity of this method [49].
In assessing QoL after TG, a significant problem is that 
it is the size of meals consumed that often prolongs the 
period of convalescence. The next step in the development 
of gastric surgery was thereby focused on reconstructing the 
gastrointestinal tract so that a food reservoir was created. 
For the aforementioned reconstruction methods, only the 
ileo-caecal segment fulfils this role. Just as reconstruction 
without food reservoirs, such methods can be divided into 
two groups according to whether duodenal passage is re-
tained or not. In 1952, Hunt and Lawrence were the first to 
propose creating a J-shaped reservoir (J-Pouch) which did 
not preserve duodenal passage, but was modified in 1976 
by Herfarth through the jejunoplication anastomosis; this 
still being successfully used up till now [50–52]. Reconstruc-
tions that create an intestinal reservoir by duodenal closure 
were also suggested by Tomoda and Nakayama [53] whilst 
Lygidakis proposed avoiding intestinal dilation and slow-
ing passage by forming two reservoirs separated by a 5 cm 
segment without anastomosis [54]. Horwath proposed 
creating a 15cm long reservoir with two anti-peristaltic 
anastomised loops forming a Y-shaped pouch (i.e. aboral 
pouch) [55]. Methods for constructing food reservoirs are 
more complex and time consuming, and thereby require 
extensive experience in gastric surgery by the surgeon. 
Upon reviewing the literature, the observed effects of im-
proving QoL and nutritional parameters in patients after TG 
for reconstruction without any reservoirs do not meet the 
desired outcomes. Thus, reconstructions using R-Y methods 
and L-H interpositions are still the simplest and most com-
monly used methods for restoring the continuity of the 
gastrointestinal tract after TG.
Minimally invasive surgery
Access via minimally invasive surgery was pioneered 
using GC surgery at a Japanese centre. The first laparosco-
py-assisted distal gastric resection was performed in 1994 
Kitano et al. [56], and the first TG (due to cancer) by Azagra 
et al. (Belgium) in 1995 [57]. At present, using laparoscopy 
is uncontroversial when making pre-operative diagnoses of 
gastric cancer particularly in advanced disease stages. Ac-
cording to NCCN recommendations, using laparoscopy for 
diagnostic purposes are made in cases whenever diagnos-
Figure 2. Roux-en-Y reconstruction. No duodenal passage Figure 3. Longmire-Henley reconstruction. Duodenal passage retained
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ing T3–4 or N + tumours is in any doubt. At lower stages of 
clinical advancement, the chances of diagnosing metastases 
is low (4% vs 25%), even when aided by laparoscopic-ultra-
sound examination; Power et al. [58]. Laparoscopic access in 
GC surgery is slowly gaining more and more adherents. Nev-
ertheless it is difficult to unequivocally address all concerns 
about minimally invasive surgery because most publications 
report short series cases.
For this reason, both ESMO and NCCN recommends 
that minimally invasive access requires further prospective 
studies for due consideration. Husher et al. [59] reported 
on the first prospective study which compared open tech-
niques in conjunction with laparoscopy to distal gastrec-
tomy [59]. Long-term results have shown no differences 
in OS, but have however demonstrated shorter hospital 
stays, reduced blood loss and the starting of oral nutrition 
earlier for those undergoing laparoscopy. Controversies 
abound on questions concerning the completeness of re-
section as well as that of regional lymphadenectomy with 
local recurrences occurring or implants in such areas after 
trocar puncture. Laparoscopic gastric surgery undoubtedly 
requires the surgeon to be extensively experienced. Initially, 
such surgical access was preferred when dealing with less 
advanced (T1–T2) tumours in the distal part of the stomach. 
This procedure is widely supported in Japan, where the 
incidence of contracting early gastric cancer (EGC) reaches 
50%. Concerns over retaining a QoL are reasons for consid-
ering wedge resection for Tis or T1a tumours, although for 
such patients endoscopic dissection can also be a surgical 
treatment option [60–62]. For T1b tumours located in the 
body of the stomach, wedge resection is considered while 
maintaining the prepyloric area, gastro-intestinal anasto-
mosis and D1 lymphadenectomy [63]. In Japan in 2010, 
42% of SGs are performed through laparoscopic access [64]. 
It is currently believed that minimally invasive surgery can 
also used in more advanced cases [65–68], where its out-
comes largely depend on the experience of the centre. 
Some practitioners tend to gain laparoscopic access using 
a port for lending the hand assistance, especially that the 
wound needed for removal has a similar size [69, 70]. The 
risk of local recurrence or implants in the post-trocar channel 
occurs mainly in advanced cases and can be limited by an 
appropriate surgical technique. It should be remembered 
though that laparoscopic access cannot reduce the onco-
logical extent of the resection.
Conclusions
In spite of the progress made in other areas of oncol-
ogy, the surgeon and the quality of their experience are still 
the only sure guarantee for treating GC. The effectiveness 
of combination therapy does not obviate the surgeon of 
responsibility for resecting to the correct extent (partial or 
total gastric removal with at least a 5 cm macroscopically 
healthy margin) taking into account regional lymph nodes 
removal (D2 lymphadenectomy excepting T1N0–D1 tu-
mours). Minimally invasive access, if keeping to oncological 
standards, is equivalent to open cancer surgery, particularly 
for less advanced tumours of the distal stomach. A correct/ 
/appropriate reconstruction of the digestive tract still re-
mains a determinant for the QoL after TG.
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